Ocugen Clears OCU410 Phase 3 and Extends Cash Into 2028

The Tip Desk · August 7, 2026 · 3 min read

Cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026, after a $130.0 million convertible notes close.

Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blindness, received U.S. Food and Drug Administration clearance to start the OCU410 Phase 3 ArMaDa3 trial for geographic atrophy and was granted Regenerative Medicine Advanced Therapy designation, a step that the company said enables eligibility for priority review and accelerated approval.

The company said the planned combined global Phase 3 trial of about 237 subjects, powered at 95% for the primary end point, is on track to initiate in the quarter, with BLA and MAA filings targeted for 2028. Phase 2 ArMaDa 12-month data showed a statistically significant 31% reduction in GA lesion growth versus control at the dose planned for Phase 3.

Cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026, compared with $32.2 million as of March 31, 2026. Ocugen closed an offering of $130.0 million aggregate principal amount of 6.75% convertible senior notes due 2034, including full exercise of a $15.0 million over-allotment, for net proceeds of about $112.5 million. About $32.7 million of those proceeds retired the Avenue Capital loan, eliminating 12.25% interest-rate debt from the capital structure. The company said the offering extends cash runway into 2028.

Long-term debt, net, fell to $1.729 million at June 30, 2026, from $27.542 million at Dec. 31, 2025. Convertible notes of $82.359 million and a derivative liability of $33.708 million appeared on the June 30 balance sheet. Common shares outstanding were 339.0 million.

OCU410ST for Stargardt disease completed enrollment and dosing of 63 subjects ahead of schedule in less than nine months in the pivotal Phase 2/3 GARDian3 trial. Topline results are anticipated in the second quarter of 2027, with a BLA to follow in mid-2027.

OCU400 for retinitis pigmentosa finished enrollment in liMeliGhT (N=140), which the company described as the first and largest genetic medicine registrational trial for broad RP patients spanning more than 30 genetic mutations. FDA feedback confirmed that the path to a rolling BLA remains tied to topline data expected in the first quarter of 2027. The company successfully completed Process Performance Qualification batches supporting BLA and commercial launch supplies.

Ocugen signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to negotiate an exclusive OCU400 license in retinitis pigmentosa across the Middle East and North Africa, with up to $255 million in sales milestones, a 22% royalty on net sales, and a moderate upfront payment.

For the three months ended June 30, 2026, collaborative arrangement revenue was $1.488 million, versus $1.373 million a year earlier. Research and development expense rose to $10.690 million from $8.402 million. General and administrative expense was $7.242 million. Total operating expenses were $17.932 million.

Net loss widened to $24.877 million, or $0.07 a share, from $14.739 million, or $0.05 a share, a year earlier. Interest expense increased to $4.476 million from $1.285 million. The quarter included a $2.383 million loss on extinguishment of debt and a $1.891 million change in fair value of derivative liability that were zero a year earlier.

Mohamed Genead was named Chief Medical Officer on June 11, 2026, and Chris Clark was named Vice President, Corporate Communications on July 16, 2026.

The company remains on track to announce top-line results for OCU400 in 1Q 2027 and for OCU410ST in 2Q 2027.